Daily non-political popular news in brief.

Research shows survival benefit for leukemia patients treated with arsenic trioxide

Through participation in a government-sponsored multi-year study, researchers at the Comprehensive Cancer Center at Wake Forest University have helped confirm that arsenic trioxide -- marketed as Trisenox -- significantly improves patient survival when coupled with standard chemotherapy treatment in newly diagnosed patients with acute promyelocytic leukemia, or APL.

Read more »

Keywords: research, shows, survival, benefit, leukemia, patients, treated, arsenic, trioxide, show, patient

« Previous | Next »

Similar news on "Research shows survival benefit for leukemia patients treated with arsenic trioxide":

1. 2 carotid artery stenting studies show results comparable to AHA guidelines
   10-23-2007 · EurekAlert!
   Two carotid stenting trials examining patient outcomes demonstrated results that are comparable to guidelines established by the American Heart Association for patients treated with carotid artery surgery. The results of these studies were presented today at the Cardiovascular Research Foundation's 19th annual Transcatheter Cardiovascular Therapeutics.
   Similar news · Read more »
   
2. Drug/intervention combinations offer benefit in severe CVD
   03-26-2007 · EurekAlert!
   While millions of Americans suffer from severe cardiac dysfunction, only about 3,000 heart transplants are possible each year. In the meantime, doctors are trying to identify new combinations of medicines and interventions that will increase survival rates among this high-risk population. Research presented today at the American College of Cardiology's 56th Annual Scientific Session offers new insight into the most effective therapies for patients with severe left ventricular dysfunction, cardiogenic shock and perioperative hypertension.
   Similar news · Read more »
   
3. 1-year results of bronchial thermoplasty in refractory asthma
   02-11-2008 · EurekAlert!
   Data from the Research in Severe Asthma trial of bronchial thermoplasty published in the American Journal of Respiratory and Critical Care Medicine show that patients experienced long term improvement in pulmonary function, improved quality of life and asthma control, and a reduction in rescue medication use for patients treated with bronchial thermoplasty.
   Similar news · Read more »
   
4. Combining therapies can improve survival for early-stage breast cancer patients
   04-03-2007 · EurekAlert!
   Patients with early-stage breast cancer who are treated with both chemotherapy and tamoxifen have a higher survival rate than patients who receive only tamoxifen. But a combination of tamoxifen and ovarian suppression -- treatment to stop the ovaries from functioning -- did not show any additional benefits, according to two randomized clinical trials published in the April 4 Journal of the National Cancer Institute.
   Similar news · Read more »
   
5. First antisense drug provides benefit to subset of chronic lymphocytic leukemia patients
   02-14-2007 · EurekAlert!
   The first "antisense" drug to be tested in chronic lymphocytic leukemia (CLL) shows benefit in a phase III clinical trial for a specific subset of patients - those who are still sensitive to a chemotherapy drug often used to treat this cancer.
   Similar news · Read more »
   
6. Jefferson oncologists show less radiation just as effective in fighting brain tumor, saving hearing
   11-07-2006 · EurekAlert!
   Radiation oncologists have found that giving less radiation than usual is just as effective against a benign but potential devastating brain tumor called an acoustic schwannoma, and better yet, might save more of the patient's hearing. They compared two groups among 115 patients with acoustic schwannomas treated at Thomas Jefferson University Hospital between 1994 and 2005. Both had effective tumor control, but those who received the lower radiation dose had more hearing preserved.
   Similar news · Read more »
   
7. Early Phase II results show bosutinib safe, effective for CML
   12-11-2007 · EurekAlert!
   A new drug for chronic myelogenous leukemia works for patients who have developed resistance to frontline therapy and causes fewer side effects than other medications in its class, a research team led by scientists at the University of Texas M. D. Anderson Cancer Center reports at the 49th annual meeting of the American Society of Hematology.
   Similar news · Read more »
   
8. Penn's Abramson Cancer Center part of major phase III study for myeloma
   11-21-2007 · EurekAlert!
   Researchers from the UPenn's Abramson Cancer Center announced today that findings from two international clinical trials show unprecedented survival for patients with myeloma, a cancer the blood-making cells of bone marrow. Findings show that with the oral drug lenalidomide, in combination with dexamethasone, patients significantly improved by all measures where previous treatments had failed -- including a median survival of nearly three years -- the longest median survival known for this difficult to treat patient group.
   Similar news · Read more »
   
9. Pancreatic cancer markers identified, may predict survival
   05-01-2007 · EurekAlert!
   Scientists have discovered a way to distinguish pancreatic cancer from non-cancerous tissue, new research shows. The method may also distinguish patients who will survive longer than two years.
   Similar news · Read more »
   
10. Studies suggest key correlation between lung cancer subtype and treatment outcomes
    09-26-2007 · EurekAlert!
    In clinical research, patients with advanced non-small cell lung cancer that are classified as having a non-squamous histology achieve statistically significant higher survival when treated in the second-line setting with ALIMTA (pemetrexed for injection) when compared to histologically-similar patients treated with docetaxel.
    Similar news · Read more »